Cannabis Use and Associated Harms among Schizophrenia Patients in a Nigerian Clinical Setting: A Case–Control Study by Victor Lasebikan & Olaolu O. Aremu
August 2016 | Volume 7 | Article 1361
Original research
published: 03 August 2016
doi: 10.3389/fpsyt.2016.00136
Frontiers in Psychiatry | www.frontiersin.org
Edited by: 
Marijn Lijffijt, 
Baylor College of Medicine, USA
Reviewed by: 
Liangsuo Ma, 
University of Texas Health Science 
Center at Houston, USA  
Robert F. Leeman, 
University of Florida, USA
*Correspondence:
Victor Lasebikan  
victorlash@yahoo.com
Specialty section: 
This article was submitted to 
Addictive Disorders, 
a section of the journal 
Frontiers in Psychiatry
Received: 18 March 2016
Accepted: 21 July 2016
Published: 03 August 2016
Citation: 
Lasebikan V and Aremu OO 
(2016) Cannabis Use and Associated 
Harms among Schizophrenia 
Patients in a Nigerian Clinical 
Setting: A Case–Control Study. 
Front. Psychiatry 7:136. 
doi: 10.3389/fpsyt.2016.00136
cannabis Use and associated 
harms among schizophrenia 
Patients in a nigerian clinical 
setting: a case–control study
Victor Lasebikan1* and Olaolu O. Aremu2
1 Department of Psychiatry, College of Medicine, University of Ibadan, Ibadan, Nigeria, 2 Psychiatric Unit, Ring Road State 
Hospital, Ibadan, Nigeria
aim: The overall aim of this study was to determine the prevalence of cannabis use 
among patients with schizophrenia with associated levels of harm in a Nigerian clinical 
setting.
Method: In this case–control study, consecutive 150 patients with schizophrenia were 
matched by age and gender with an equal number of patients that utilized the general 
outpatient department of the State Hospital, Ring Road Ibadan. The alcohol, smoking 
and substance involvement screening test (ASSIST) was used to obtain prevalence of 
cannabis use and level of health risk as determined by the ASSIST score. The positive 
and negative syndrome scale was used to determine the severity of psychosis.
results: Prevalence of cannabis use among the cases and control group was 10.0 and 
2.7%, respectively, p = 0.03. Mean ASSIST score was significantly higher among the 
cases compared with the control, p < 0.001. Respondents of male gender and those 
who were not married were significantly more likely to be cannabis users among patients 
with schizophrenia (p < 0.001 and p < 0.02), respectively.
conclusion: Cannabis use was prevalent among patients with schizophrenia and 
was associated with health risks. Thus, routine screening for cannabis use and brief 
intervention is suggested to be integrated into care for adolescents and adults with 
schizophrenia.
Keywords: cannabis, screening and brief intervention, schizophrenia, health risks
inTrODUcTiOn
A substantial body of evidence from developed countries of the world indicates an association 
between adolescent cannabis use and schizophrenia (1–3). Cannabis users have also been found 
to be three times more likely to develop schizophrenia (4). Research findings from Nigeria (5, 6) 
corroborate those from the Western countries that mental disorders are highly prevalent among 
cannabis users and account for the majority of drug-related admissions in Nigerian psychiatric care 
facilities (7).
There are several plausible mechanisms for this association. For example, administration of 
very high doses of tetrahydrocannabinol to healthy individuals can produce transient psychotic-like 
symptoms (2). Thus, it is either that cannabis is a risk factor for the development of schizophrenia 
or its use in schizophrenia may be to self-medicate the negative symptoms of schizophrenia, since 
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conventional antipsychotics do not treat negative symptoms (8). 
This is because cannabis stimulates dopamine release (9), the 
level of which is low in negative symptoms. Consistent with 
this is the reported higher rates of cannabis use in people with 
schizophrenia than in the general population (10). Nevertheless, 
prospective and retrospective studies indicate that the onset 
of cannabis use typically precedes that of schizophrenia (11), 
somehow revoking the self-medication hypothesis.
Other models that have emerged in the past decades include 
genetic influences and early environmental hazards, leading to 
neurodevelopmental problems (12, 13). Furthermore, the expres-
sion of the cannabis-1 (CB-1) receptor reaches a peak around the 
onset of adolescence, implying that the effects of cannabis on the 
brain are heightened during this period (14), which is a period 
just before the peak age of onset of schizophrenia.
Although cannabis use among healthy users may be associated 
with cognitive impairments (15), structural brain abnormalities, 
and subthreshold psychotic symptoms (16), cannabis has been 
found to have some beneficial effects on cognition in a sub-
population of patients with schizophrenia (17), thereby having 
implications for its continued use.
The occurrence of cannabis use within schizophrenia poses a 
significant burden on patients in terms of outcome (18) and cost 
of treatment. Considering the health indices of Nigeria, where 
access to formal mental health care is poor (19), cannabis use in 
schizophrenia is expected to be associated with poorer outcomes, 
a higher level of disability, and poorer quality of life. It is, therefore, 
important to derive data on the correlates of cannabis use among 
patients with schizophrenia in this environment, the findings of 
which may be applicable to the development of an intervention 
program for this population.
The overall aim of this study was to determine the prevalence 
of cannabis use among patients with schizophrenia in the psychi-
atric unit of the State Hospital, Ring Road, Ibadan compared with 
patients attending the general outpatient department (GOPD) of 
the same hospital, for simple ailments. The sociodemographic 
correlates of cannabis use, the association between symptom 
profile of schizophrenia, and the level of cannabis-induced health 
risk was also sought. It was hypothesized that cannabis use would 
be more significantly prevalent among patients with schizophre-
nia compared with the control.
MeThODOlOgY
The study was carried out in the psychiatric unit and the GOPD of 
the State Specialists Hospital, Ring Road, Ibadan, the capital city 
of Oyo State. The city is located in the South-Western part of the 
country and is the oldest state capital in Nigeria.
The GOPD is the first port of call for all patients. Since patients 
do not require referral to be attended to at this point, it is a walk-
in clinic, making it a de facto primary care center. At the GOPD, 
the Medical Officer on duty first attends to all patients and sorts 
them to the various clinics, including the psychiatric clinic.
study Design
This was a case–control brief intervention study and the find-
ings reported herein are the results of our baseline assessment. 
The outcome of the brief intervention will be subsequently 
published. The cases were patients with schizophrenia while the 
control group was patients with simple ailments that attended 
the GOPD of the same study center for simple ailments during 
the study period. Cases were selected by a multistage sampling 
method.
In the preliminary stage of the study, the sample frame was 
determined by obtaining, from the medical records department, 
the inventory of patients who utilized this specialist clinic in a 
12-month calendar year. An average of 250 new patients with 
schizophrenia was found to have utilized the facility in the past 
year. This constituted the sample frame.
The sample size of the present study was determined using 
the sample size estimation table for a given sample frame (20). 
According to the table, for a sample frame of 250, the minimum 
sample size required to be studied is 152, at 95% CI. Thus, a 
minimum sample of 152 was sought.
sample selection
Participants who met study criteria were consecutively recruited. 
All patients who utilized the psychiatric unit of the State Hospital, 
Ring Road, Ibadan, were initially screened with the psychosis 
screening questionnaire (21). Those who screened positive had 
the structured clinical interview for DSM-IV axis I disorder 
(SCID) administered to them. Those with diagnoses of schizo-
phrenia proceeded to the second stage of the study, in which the 
Alcohol and Substance Involvement Screening Test (ASSIST) was 
administered to determine the prevalence of cannabis use and 
the risk of health problems, the procedure of sample selection is 
shown in Figure 1.
Inclusion Criteria
All participants were required to meet DSM-IV criteria for 
schizophrenia and must have been suffering from the illness for 
a period of at least 2 years. They were also expected to be accom-
panied by a principal caregiver with whom collateral information 
could be obtained.
Exclusion Criteria
 1. Patients with schizoaffective disorder and affective psychosis.
 2. Patients with any major general medical conditions.
 3. Patients who were not accompanied by any principal caregiver.
Control Group
The control group consisted of patients who attended GOPD of 
the State Hospital, Ring Road, Ibadan, for simple ailments during 
the study period. The SCID was also administered to the control 
group.
Exclusion Criteria for the Control Group
 1. Patients with any lifetime or current DSM-IV axis I disorder, 
according to the SCID.
 2. Patients with a lifetime or current DSM-IV axis II disorder, 
according to the SCID.
 3. Patients with a family history of any psychiatric illness were 
also excluded.
Patients in the control group who met eligibility criteria were 
matched by age and gender with those with schizophrenia. 
FigUre 1 | sampling technique. Stage 1: study population divided into two groups. Stage 2: psychosis screen administered. Stage 3: SCID administered. 
Stage 4: eligibility.
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This was because of the effect of age and gender on the prevalence 
of drug use, according to previous literature (22).
Caregiver
For the purpose of this study, a caregiver was defined as “a non-
professional person in the community who was most involved 
with the everyday care of the case and would be very likely to 
respond to any request for special assistance at any time, if such a 
request was made by the case” (23).
ethical considerations
Permission for the study was obtained from the ethical and 
review board of the Ring Road State Hospital as directed by the 
department of planning, research, and statistics, the ministry 
of health Oyo state, to ascertain that the study met criteria for 
human research for experiments involving human beings.
Informed consent was obtained from each of the patients and 
or their relations, after the study was fully explained to them.
Measures
Sociodemographic Questionnaire
Information about sociodemographic characteristics of respond-
ents, including the age of respondents, gender, educational back-
ground, the age at the onset of illness, and duration of untreated 
psychosis was obtained.
The Psychosis Screening Questionnaire
The psychosis screening questionnaire (21) is a simple 6-item yes/
no option instrument that probes into lifetime history of hypoma-
nia, thought interference, persecution, perceptual abnormalities, 
strange experiences, and hallucination. This short instrument is 
also a valid instrument for screening for psychosis and has been 
previously used in Nigeria (23).
World Mental Health Structural Clinical Interview for 
DSM-IV Axis 1 Disorder 2010 Version (SCID)
The SCID (24) was used to generate diagnoses of the subjects. The 
instrument covers all the criteria for the diagnoses included in the 
various modules. The interviewer makes a clinical judgment as 
to whether each criterion is met. The instrument is available in a 
patient edition for use with subjects who have been identified as 
psychiatric patients and in a non-patients edition suitable for use 
in epidemiological studies.
Positive and Negative Syndrome Scale
Positive and negative syndrome scale (PANSS) is a 30-item, 
7-point rating instrument that has adapted 18 items from the 
Brief Psychiatric Rating Scale (BPRS) (25) and 12 items from 
the Psychopathology Rating Schedule (PRS) (26). The PANSS 
addresses both the presence and severity of symptoms, and the 
highest applicable rating point is always assigned, even if the 
patient meets criteria for lower ratings as well. Of the 30 psychi-
atric parameters assessed on the PANSS, 7 were chosen a priori 
to constitute a positive scale, 7 make up a negative scale and the 
remaining 16 general psychopathology.
The Alcohol, Smoking and Substance Involvement 
Screening Test
The ASSIST was used to obtain information about lifetime and 
current cannabis use.
The ASSIST is a cross-culturally validated instrument that was 
developed by the World Health Organization to screen for drugs, 
alcohol, and tobacco use in high prevalence settings and has been 
previously used in Nigeria (27).
The ASSIST-linked brief intervention is a short intervention 
lasting 3–15 min given to clients who have been administered 
the ASSIST by a health worker. The ASSIST screens for the 
use of all substance types (tobacco products, alcohol, canna-
bis, cocaine, amphetamine-type stimulants (ATS), sedatives, 
hallucinogens, inhalants, opioids, and “other” drugs) and 
determines a risk score (“lower,” “moderate,” or “high”) for 
each substance (28).
The risk scores are recorded on the ASSIST feedback report 
card, which is used to give personalized feedback to clients by 
presenting them with the scores that they have obtained and the 
associated health problems related to their level of risk. Asking 
clients if they are interested in viewing their scores allows the 
health worker to commence a discussion (brief intervention) 
with the client in a non-confrontational way.
Screening and brief intervention aim to identify current or 
potential problems with substance use and motivate those at risk 
to change their substance use behavior by creating a connection 
between their current pattern of use and the associated risks and 
harms (29). In general, brief interventions in primary care ranges 
from 3 min of brief feedback and advice to 15–30 min of brief 
counseling (30).
Scoring
For drugs such as cannabis, scores of 0–3 indicates lower risk, 
4–26 moderate risk, and 27 and above, high risk.
The modality of the brief intervention is determined by the 
risk score. For clients scoring in the lower risk range (0–3), 
general health advice is given; for a moderate risk score (4–26), 
brief intervention and take-home booklet and information are 
prescribed; while for high-risk score (>26) brief intervention, 
take-home booklet, and information and referral to specialist 
hospital for assessment and treatment constitute the components 
of the intervention.
The outcome of the intervention given to the sample studied in 
the current study is beyond the scope of this report.
Data Management and analyses
The questionnaires were serialized, cleaned, edited, and safely 
stored. Thereafter, the information yielded by each respondent 
was entered directly into the computer using the SPSS software 
version 15.0 (SPSS, Inc., Chicago, IL, USA). Chi-square statistics 
were used to analyze categorical data for within-group com-
parisons of patients with schizophrenia. All Chi-Square were 
Yates-corrected for a 2 × 2 comparison or Bonferroni-corrected 
when there were multiple comparisons. Whenever a cell was <5 
in any 2 ×  2 table, Fisher’s exact test was used. The McNemar 
test was used to determine significant differences in two-level 
TaBle 1 | sociodemographic characteristics of respondents.
Variables cases N = 150 control N = 150 statistics
N % N % rr(ci) p
age (years)
<25 46 30.7 42 28.0 1.06 (0.83–1.36) 0.70
25–34 54 36.0 44 29.3 1.16 (0.92–1.46) 0.26
35–44 30 20.0 34 29.7 0.92 (0.69–1.23) 0.67
>44 20 13.3 30 20.0 0.76 (0.54–1.10) 0.16
gender
Male 58 38.7 70 46.7 0.84 (0.67–1.07) 0.20
Female 92 61.3 80 53.3
Marital status
Married 68 45.3 124 82.7 0.46 (0.37–0.54) <0.001
Unmarried 82 54.7 26 17.3
employment status
Employed 76 50.7 142 94.7 0.38 (0.32–0.47) <0.001
Unemployed 74 49.3 8 5.3
education
No formal 8 5.3 10 6.7 0.88 (0.52–1.50) 0.81
Elementary 26 17.3 30 20.0 0.91 (0.67–1.24) 0.66
Secondary 72 48.0 64 42.7 1.11 (0.88–1.40) 0.42
Tertiary 44 29.3 46 30.7 0.95 (0.71–1.28) 0.88
Occupation
High level professional 1 0.7 7 4.7 0.24 (0.04–1.54) 0.07
Skilled worker 15 10.0 80 53.3 0.24 (0.15–0.39) <0.001
Semi-skilled/unskilled 60 40.0 55 36.7 1.07 (0.85–1.35) 0.64
Unemployed 74 49.3 8 5.3 2.59 (2.13–3.15) <0.001
religion
Christianity 53 35.3 48 32.0 1.08 (0.85–1.36) 0.63
Islam 97 64.7 102 68.0
ethnicity
Yoruba 90 60.0 85 56.6 1.07 (0.85–1.35) 0.64
Igbo 35 23.3 40 26.7 0.91 (0.69–1.20) 0.59
Hausa 15 10.0 12 8.0 1.12 (0.79–1.61) 0.69
Minority tribes 10 6.7 13 8.7 0.86 (0.53–1.39) 0.66
Current Cannabis use 15 10.0 4 2.7 1.64 (1.26–2.14) 0.02
Mean (SD)ASSIST Score 19.87 5.31 3.00 0.81 6.2t <0.001
assisT score/health risks
0–3 (Low health risk) 1 25.0 3 75.0 5.2X 0.02FE
4–26 (Moderate health risk) 14 93.3 1 6.7
>26 (Severe health risk) – – – –
FE, Fisher’s Exact p-value; t, Independent t-test; X, Chi square.
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categorical variables between the cases and the control and con-
ditional logistic analyses was used for multilevel categorical data. 
The Independent t-test was used to test for differences between 
the mean scores of the two groups. The association between can-
nabis use and PANSS score among patients with schizophrenia 
was determined using Pearson correlation. Since the response to 
cannabis use was bivariate and that of PANSS was multinomial, 
each of the PANSS subscales was dichotomized using the median 
score for carrying out the correlation analysis. A correlation 
analysis was also carried out between each of the subscales of 
the PANSS and the ASSIST. A Bonferroni correction was made 
for each of the p-value obtained by dividing the critical p-value 
of 0.05 with the number of comparisons made, i.e., 0.05/4, in the 
case of correlation analysis. All analyses were carried out within 
95% CI, p < 0.05.
resUlTs
A significantly higher proportion of patients with schizophrenia 
were unmarried and unemployed compared with the control, 
p < 0.001. Prevalence of cannabis use among the cases and the 
control group was 10.0 and 2.7%, respectively. This was signifi-
cant at p = 0.03. Mean ASSIST score was also significantly higher 
among the cases compared with the control, t = 6.2, p < 0.001. A 
significantly higher proportion of cases were at moderate health 
risk from cannabis use compared to those who were at low health 
risk, p = 0.02 (Table 1).
Respondents who were of the male gender and those who 
were not married were significantly more likely to be cannabis 
users among patients with schizophrenia, p < 0.001 and p = 0.01, 
respectively (Table 2).
TaBle 2 | sociodemographic characteristics of cannabis use among 
patients with schizophrenia (N = 150).
Yes no
n % N % χ2 p
age (years)
<25 – – 16 100.0 4.8 0.2
25–34 7 15.9 37 84.1
35–44 2 5.0 38 95.0
>44 6 12.0 44 88.0
gender
Male 13 22.4 45 77.6 15.7 <0.001FE
Female 2 2.2 90 97.8
Marital status
Married 2 2.9 66 97.1 5.2 0.01FE
Unmarried 13 15.9 69 84.1
employment status
Employed 7 9.2 69 90.8 0.1 0.7
Unemployed 8 10.8 66 89.2
education
No formal – – 8 100.0 3.3 0.07
Elementary – – 26 100.0
Secondary 13 18.1 59 81.9
Tertiary 2 8.7 42 95.5
Duration of illness
<3 years 6 7.9 70 92.1 0.8 0.4
≥3 years 9 12.2 65 87.8
religion
Christianity 6 7.9 70 92.1 0.8 0.4
Islam 9 12.2 65 87.8
ethnicity
Yoruba 10 11.0 80 89.0 0.7 0.8
Igbo 4 11.0 31 89.0
Hausa – – 15 100.0
Minority tribes – – 10 100.0
FE, Fisher’s exact.
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After Bonferroni correction, there was a significant correlation 
between cannabis use and Negative PANSS and also with total 
PANSS (p < 0.001 and p = 0.003), respectively (Table 3). Also, 
after Bonferroni correction, among patients with schizophrenia 
who were also current cannabis users, there was a significant cor-
relation between ASSIST scores and negative PANSS on the one 
hand and ASSIST scores and general psychopathology subscale of 
the PANSS on the other hand. There was also a significant correla-
tion between ASSIST scores and total PANSS score (p < 0.001) 
(Table 4).
DiscUssiOn
In this case–control study, 150 patients with schizophrenia were 
compared with an equal number of controls. Prevalence and 
determinants of cannabis use and associated health risk based 
on the ASSIST score were sought. Prevalence of cannabis use was 
10.0% among the cases and 2.7% in the control group. Cannabis-
related health risk as determined by the ASSIST score was signifi-
cantly higher among patients with schizophrenia. Male gender 
and presence of psychopathology were found to be significant 
predictors of cannabis-related health risk.
To the best of the author’s knowledge, this is the first study on 
this subject matter in Nigeria. Thus, comparisons of the findings 
from the present study will be based on research from other parts 
of the world.
sociodemographic characteristics of 
Patients
The sample of patients with schizophrenia was generally charac-
terized by relatively young age compared with the controls. The 
mean age of the sample with schizophrenia was 34.3 ± 11.6 years. 
This was lower than the 38.7 ± 11.4 years obtained by Gureje and 
colleagues in 2002 (31). This finding is in line with the report of 
epidemiological catchment study, indicating that schizophrenia 
is commoner in the younger age group (32). In the present study, 
a higher proportion of the patients with schizophrenia were 
unmarried and unemployed, compared with the control group. 
Although it is difficult to determine which one preceded the other 
between being unmarried and psychoses, it has been found that 
patients with schizophrenia often live alone, were unmarried 
(33), and were unemployed (34). We found that male gender 
and being unmarried were associated with cannabis use among 
subjects with schizophrenia. This is in support of previous studies 
in this environment (22, 35). Remarkably, substance abuse tends 
to share certain sociodemographic characteristics like being 
unmarried and being unemployed with schizophrenia.
Prevalence of cannabis Use
In the present study, 10.0% of patients with schizophrenia were 
current cannabis users. This figure is within the reported range of 
8.6–28.6% from a meta-analysis involving 10 studies carried out 
about 5 years ago (36). Our finding also lends support to previous 
evidence, indicating an association between adolescent cannabis 
use and the development of schizophrenia (1, 2–3). Although a 
direct cause and effect relationship was not proven, our finding 
that cannabis use was significantly associated with negative PANSS 
score may support the self-medication hypothesis; the argument 
being that cannabis is used as an adjunct by patients to attenuate 
their negative symptoms (8). On the other hand, the observed sig-
nificant correlation between cannabis use and total PANSS score 
may suggest that cannabis use in schizophrenia is related to the 
presence of psychotic symptoms in the entire psychopathological 
process. Indeed, Kuepper and colleagues conceived cannabis use 
as impacting the symptoms of schizophrenia (37). Nevertheless, 
a common neurobiological pathway may be considered for this 
phenomenon, given a number of commonalities between schizo-
phrenia and cannabis use (38, 39).
cannabis Use and health risks among 
cannabis Users
We also found that among patients living with schizophrenia, 
who were cannabis users, only 1 was at low health risk and the 
remaining 14 were at moderate health risk. The findings have a lot 
of implications regarding the negative effects of chronic cannabis 
use. This is pertinent considering that cannabis consumption car-
ries specific risks of dependence (40), lung cancer, tuberculosis, 
other lung diseases (41), and cardiovascular diseases (40).
TaBle 3 | correlation between cannabis use and positive and negative symptoms scales in schizophrenia (N = 150).
cannabis  
use
Positive  
Panss
negative  
Panss
general Psychopathology  
Panss
Total 
Panss
Cannabis Pearson correlation 1 0.170BNS 0.298BS 0.183BNS 0.245BS
Sig. (2-tailed) 0.039 0.000 0.026 0.003
Positive PANSS Pearson correlation 0.170BNS 1 0.131 0.526BS 0.681BS
Sig. (2-tailed) 0.039 0.109 0.000 0.000
Negative PANSS Pearson correlation 0.298BS 0.131 1 0.645BS 0.752BS
Sig. (2-tailed) 0.000 0.109 0.000 0.000
General psychopathology PANSS Pearson correlation 0.183BNS 0.560BS 0.645BS 1 0.935BS
Sig. (2-tailed) 0.025 0.000 0.000 0.000
Total PANSS Pearson correlation 0.245BS 0.681BS 0.752BS 0.935BS 1
Sig. (2-tailed) 0.002 0.000 0.000 0.000
BS, Bonferonni significant; BNS, Bonferonni not significant.
TaBle 4 | correlation between assisT scores and positive and negative symptoms scale in schizophrenia (N = 15).
correlations
Positive  
Panss
negative  
Panss
general psychopathology  
Panss
Total  
Panss
assisT
Positive PANSS Pearson correlation 1 0.332BS 0.609BS 0.724BS 0.512BNS
Sig. (2-tailed) 0.009 0.006 0.000 0.025
Negative PANSS Pearson correlation 0.332BS 1 0.651BS 0.719BS 0.730BS
Sig. (2-tailed) 0.009 0.003 0.001 0.000
General psychopathology  
PANSS
Pearson correlation 0.609BS 0.651BS 1 0.950BS 0.823BS
Sig. (2-tailed) 0.006 0.003 0.000 0.000
Total PANSS Pearson correlation 0.724BS 0.719BS 0.950BS 1 0.844BS
Sig. (2-tailed) 0.000 0.001 0.000 0.000
ASSIST Pearson correlation 0.512BNS 0.730BS 0.823BS 0.844BS 1
Sig. (2-tailed) 0.025 0.000 0.000 0.000
BS, Bonferonni significant; BNS, Bonferonni not significant.
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Notable is the association between ASSIST scores and nega-
tive PANSS score, ASSIST scores and general psychopathology 
subscale of PANSS scale, as well as ASSIST scores and total 
PANSS score. This, by implication, suggests that the more severe 
the symptoms of schizophrenia the more grave the health risks of 
cannabis smoking. It is conceivable that individuals suffering from 
schizophrenia are not likely to seek treatment for their cannabis 
use or that they have difficulties adhering to a substance abuse 
treatment program. They are also more likely to have continued 
cannabis use, leading to clinical exacerbation, non-compliance 
with antipsychotic medications, and poor overall health.
The finding that 2.7% of service users in a walk-in clinic used 
cannabis is also an important epidemiological finding. Although 
a higher rate, about fourfold, was reported in a non-psychotic 
population over 10 years ago (42); this finding is notable consid-
ering the potential health risks associated with cannabis smoking. 
More so, none of them had ever sought treatment for their can-
nabis use.
implication of the study
The results of the present study have implications for cannabis use 
screening in patients with schizophrenia. This is because of the 
complex association between cannabis use and schizophrenia. 
Great consideration for simultaneous implementation of a can-
nabis cessation program during treatment for schizophrenia is 
required, given the associated health risks.
The current study has a number of limitations. The prevalence 
of cannabis use could have been masked by significant under-
reporting, given the sensitive nature of the question. Obtaining 
information on substance use without a face-to-face contact has 
been long recognized in improving response rate (43). The clini-
cal state of the patient could also have led to difficulty in obtaining 
information about cannabis use, if the caregiver was not aware of 
such. Also, toxicological screen was not carried out, because of 
the economic implication of the study.
Our findings should be interpreted with caution, given the 
small sample size. This also limits the generalization of the 
research findings. However, an important strength of this study 
was the detection of a subsample of patients with schizophrenia 
and the control group who benefited from screening and brief 
intervention for cannabis use.
In conclusion, cannabis use is fourfold more prevalent in 
patients with schizophrenia. About 1 in every 40 persons in a 
de facto primary care, in this instance, the general outpatients’ 
department, a walk-in clinic use cannabis. Cannabis use in 
patients with schizophrenia is associated with moderate health 
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risk. Although the present study has not established a causal 
relationship between cannabis use and schizophrenia, it should 
serve as a template for large-sample size prospective studies in 
Nigeria. Such study design may shed more light on the relation-
ship between cannabis use and symptoms of schizophrenia.
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